SELLAS up 85% premarket on positive mid-stage NeuVax data [Seeking Alpha]
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: Seeking Alpha
SELLAS up 85% premarket on positive mid-stage NeuVax dataThinly traded nano cap SELLAS Life Sciences Group (SLS+84.6%) is up on increased volume in response to itsannouncement positive preliminary data from a Phase 2b clinical trial assessing the combination of Roche's Herceptin (trastuzumab) and NeuVax (nelipepimut-S) in HER2 1+/2+ breast cancer patients in an adjuvant setting to prevent cancer recurrence.After median follow-up of 19 months, patients receiving Herceptin + NeuVax experienced a clinically meaningful improvement in median disease-free survival. In a subgroup of patients with triple-negative breast cancer (TNBC), there was a 70.4% reduction on the relative risk of cancer recurrence compared to control. In patients not receiving hormonal therapy, the relative reduction in risk of cancer recurrence was 74.1% versus control.The company says it plans to meet with the FDA and EMA for clarify a development and regulatory path for the combination in TNBC patients. It also will
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study [Yahoo! Finance]Yahoo! Finance
- SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL StudyGlobeNewswire
- SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
SLS
Sec Filings
- 3/28/24 - Form S-3
- 3/28/24 - Form S-3
- 3/28/24 - Form 8-K
- SLS's page on the SEC website